Skip to content
Screener

Glaukos GKOS Investing Cash Flow

Investing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$1.11B+93.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$92.7M+91.5%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
-$19K+91.0%
AbbVie logo
AbbVieABBV
-$574M+21.9%
Schering-Plough logo
Schering-PloughSGP
-$1.67M-916%
Bausch + Lomb logo
Bausch + LombBLCO
-$87M+3.3%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Glaukos’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 7:30 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-193004
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Purchases of property and equipment(3,959)(1,938)
Investment in company-owned life insurance(759)(395)
Other investing activities-(750)
Net cash provided by (used in) investing activities10,504(36,948)
Financing activities
Proceeds from exercise of stock options19,3304,082
Proceeds from share purchases under Employee Stock Purchase Plan2,3812,961
Payment of employee taxes related to vested restricted stock units(5,638)(4,845)

Item 1. Financial Statements

FAQ

What is Glaukos's investing cash flow?
Glaukos (GKOS) reported investing cash flow of $10.5M in Q1 2026.
How has Glaukos's investing cash flow changed year-over-year?
Glaukos's investing cash flow increased by 128.4% year-over-year, from -$36.95M to $10.5M.
What is the long-term trend for Glaukos's investing cash flow?
Over 3 years (2021 to 2025), Glaukos's investing cash flow has grown at a 10.1% compound annual growth rate (CAGR), from -$58.23M to -$77.61M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Glaukos's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude